Paclitaxel side effects in breast cancer: activity and body composition
Part of Cancer, Skin clinical trials.
This study looks at how physical activity and body composition affect the side effects of paclitaxel, a chemotherapy drug, in women with stage II or III breast cancer. It aims to help doctors understand who might have more or fewer side effects during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman diagnosed with stage II or III breast cancer.
- You are scheduled to receive 12 weekly doses of paclitaxel (a type of chemotherapy) as part of your treatment plan.
- You are 18 years or older.
- If you've had taxane chemotherapy before, it must have ended more than a year ago.
- You must not have cognitive issues that make it hard to follow instructions, a known allergy to paclitaxel, or take medications that interact with paclitaxel.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new version of paclitaxel (albumin-bound) works the same as the approved version in people with breast cancer. It's for patients whose cancer has spread or returned after other treatments, or those for whom this drug is recommended by treatment guidelines.
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
This trial studies how paclitaxel (a chemotherapy medicine) behaves in the body when given by a specific 1-hour infusion approach. It may help refine dosing for people with cancer using measurements from scans, and it includes a medicine schedule you must match.
This study looks at whether body fat and muscle (body composition) change how well certain chemotherapy works after surgery for early breast cancer. You may be considered if you are planned to receive docetaxel as adjuvant (after-surgery) chemotherapy and have recent CT scan images.
This study looks at whether stopping routine allergy-prevention medicines before weekly paclitaxel chemotherapy affects your quality of life. If you qualify, you may be assigned to stop or continue these pre-medications and share how you feel.
This early-phase study tests how epidiferphane works in the body and whether it is safe when combined with standard chemotherapy “taxanes” (paclitaxel or docetaxel) for breast cancer. If you qualify, you may be starting a new taxane treatment plan at the study site, and you would be followed closely for side effects and drug levels.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.